← Every company
Kura Oncology Inc Patents
What Kura Oncology Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
KURA on carbonthat →Filings on file
42
Granted
3
Still pending
39
Filed under
2 names
42 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| ORAL SUSPENSIONS AND POWDER FORMULATIONS FOR RECONSTITUTION COMPRISING A MENIN INHIBITORFiled as KURA ONCOLOGY, INC.2026-01-20ROGER PAUL BAKALE | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING A MENIN INHIBITORA61P 35/00, A61K 31/519, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 9/4858, A61K 9/4866, C07D 495/04Filed as Kura Oncology, Inc.2025-12-16Jing TAO | pending |
| FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERSFiled as Kura Oncology, Inc.2025-11-26Francis BURROWS | pending |
| METHODS OF TREATING RETINAL DISEASESFiled as KURA ONCOLOGY, INC.2025-11-25FRANCIS BURROWS | pending |
| METHODS OF PREPARING MACROCYCLIC COMPOUNDS AND USES THEREOFFiled as KURA ONCOLOGY, INC.2025-11-25ROGER PAUL BAKALE | pending |
| METHODS OF TREATING SQUAMOUS CELL CARCINOMA WITH A FARNESYLTRANSFERASE INHIBITOR AND A PI3K INHIBITORFiled as Kura Oncology, Inc.2025-11-07Francis BURROWS | pending |
| TREATMENT OF NON-SMALL CELL LUNG CANCER WITH A COMBINATION OF 3-AMINO-3-(1-METHYL-1H-IMIDAZOL-5-YL)-6-OXA-2(4,6)-QUINOLINA-1,4(1,3)-DIBENZENACYCLOHEXAPHANE-22,44-DICARBONITRILE AND AN EGFR-TKIA61K 31/4178, A61K 31/4741, A61P 35/00, A61K 31/4709, A61K 31/506, A61K 45/06, A61K2300/00Filed as Kura Oncology, Inc.2025-10-17Francis BURROWS | pending |
| SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAMEC07D 215/18, C07D 491/08, A61P 35/00, A61K 9/145, A61K 9/2009, A61K 9/2013, A61K 9/2027, A61K 9/2054, A61K 9/2095, A61K 9/28, A61K 9/2806, A61K 9/282, A61K 9/2853, A61K 31/4748, C07B2200/07, C07B2200/13, C07C 55/06, C07C 55/07, C07C 57/145, C07C 57/15, C07C 59/06, C07C 59/153, C07C 59/245, C07C 59/255, C07C 59/265, C07C 65/03, C07C 65/05, C07C 65/11, C07C 309/04, C07C 309/30, C07D 295/192, C07D 401/06Filed as Kura Oncology, Inc.2025-10-03Roger Paul Bakale | pending |
| TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENINA61K 31/519, A61K 45/06, A61P 35/02, A61P 35/04, A61K 31/445, A61K 31/4523, A61K 31/4525, A61K 31/453, A61K 31/454, A61K 31/4545, A61K 31/4709, A61K 31/4725, A61K 31/506, A61K 31/517, A61K 31/53, A61K 31/5377, A61K 31/5395, A61K 31/541, C12Q 1/6869, C12Q 1/6886, C12Q2600/156Filed as Kura Oncology, Inc.2025-09-11Francis BURROWS | pending |
| CRYSTALLINE FORMS OF A MENIN INHIBITORA61K 31/519, C07D 495/04Filed as Kura Oncology, Inc.2025-08-07Roger Paul BAKALE | pending |
| METHODS OF TREATING ADVANCED SOLID TUMORSFiled as KURA ONCOLOGY, INC.2025-06-20Francis BURROWS | pending |
| METHODS OF TREATING ACUTE LEUKEMIAA61K 31/519, A61P 35/02, A61K 31/17, A61K 31/573, A61K 31/704, A61K 31/7068, A61K 38/44, C12Y 107/03003, G01N 33/5094, G01N2800/52, G01N2800/7028Filed as Kura Oncology, Inc.2025-04-30Stephen DALE | pending |
| METHODS OF TREATING ACUTE LEUKEMIAS WITH A MENIN INHIBITOR IN A COMBINATION THERAPYFiled as KURA ONCOLOGY, INC.2025-01-27MOLLIE LEONI | pending |
| ORAL SUSPENSIONS AND POWDER COMPOSITIONS FOR RECONSTITUTION COMPRISING A MENIN INHIBITORFiled as Kura Oncology, Inc.2025-01-22Roger Paul BAKALE | pending |
| TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENINFiled as Kura Oncology, Inc.2025-01-17Francis BURROWS | pending |
| SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USEC07D 519/00, A61P 35/00, A61K 9/0019, A61K 9/0053, C07D 471/10, C07D 487/04, C07D 487/10, A61K 31/5355, A61K 45/06, C07D 471/04, A61K2300/00Filed as Kura Oncology, Inc.2025-01-17Tao WU | pending |
| METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMAA61K 31/519, A61P 35/02, A61K 31/44, A61K 31/445, A61K 31/4523, A61K 31/453, A61K 31/454, A61K 31/4545, A61K 31/4725, A61K 31/505, A61K 31/5377Filed as KURA ONCOLOGY, INC.2025-01-16Francis BURROWS | pending |
| METHODS OF TREATING ACUTE LEUKEMIAS WITH A MENIN INHIBITOR IN A COMBINATION THERAPYFiled as Kura Oncology, Inc.2024-12-05Daniel G. CORUM | pending |
| METHODS OF TREATING RETINAL DISEASESFiled as Kura Oncology, Inc.2024-11-26Francis Burrows | pending |
| METHODS OF PREPARING MACROCYCLIC COMPOUNDS AND USES THEREOFFiled as Kura Oncology, Inc.2024-11-26Roger Paul Bakale | pending |
| METHODS OF TREATING KIT POSITIVE CANCERS WITH A MENIN INHIBITORFiled as KURA ONCOLOGY, INC.2024-11-15FRANCIS BURROWS | pending |
| METHODS OF TREATING ACUTE LEUKEMIAS WITH A MENIN INHIBITOR IN A COMBINATION THERAPYFiled as Kura Oncology, Inc.2024-11-04Daniel G. CORUM | pending |
| SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAMEC07D 215/18, C07D 491/08, A61P 35/00, A61K 9/145, A61K 9/2009, A61K 9/2013, A61K 9/2027, A61K 9/2054, A61K 9/2095, A61K 9/28, A61K 9/2806, A61K 9/282, A61K 9/2853, A61K 31/4748, C07B2200/07, C07B2200/13, C07C 55/06, C07C 55/07, C07C 57/145, C07C 57/15, C07C 59/06, C07C 59/153, C07C 59/245, C07C 59/255, C07C 59/265, C07C 65/03, C07C 65/05, C07C 65/11, C07C 309/04, C07C 309/30, C07D 295/192, C07D 401/06Filed as Kura Oncology, Inc.2024-11-01Roger Paul Bakale | 12466835 |
| METHODS OF TREATING KIT POSITIVE CANCERS WITH A MENIN INHIBITORFiled as Kura Oncology, Inc.2024-10-22Francis BURROWS | pending |
| CRYSTALLINE FORMS OF A MENIN INHIBITORA61K 31/519, C07D 495/04Filed as Kura Oncology, Inc.2024-09-06Roger Paul BAKALE | 12410184 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING A MENIN INHIBITORA61P 35/00, A61K 31/519, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 9/4858, A61K 9/4866, C07D 495/04Filed as Kura Oncology, Inc.2024-09-06Jing TAO | 12521396 |
| TREATMENT OF CANCER WITH MENIN INHIBITORS AND IMMUNO-ONCOLOGY AGENTSA61K 31/519, A61K 45/06, A61P 35/00, A61K 31/53, A61K 31/5377, A61K 39/39558, A61K2300/00, C07K 16/2818, C07K2317/76Filed as Kura Oncology, Inc.2024-09-04Housheng HE | pending |
| SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USEFiled as Kura Oncology, Inc.2024-08-23Tao WU | pending |
| METHODS OF TREATING ACUTE LEUKEMIAS WITH A MENIN INHIBITOR IN A COMBINATION THERAPYFiled as Kura Oncology, Inc.2024-08-07Daniel G. CORUM | pending |
| TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORSA61P 35/00, A61K 31/506, A61K 31/519, A61P 35/02, A61K 31/473, A61K 31/496, A61K 31/53, A61K 31/5377, A61K 38/13, A61K 45/06, A61K2300/00, C07D 495/04Filed as Kura Oncology, Inc.2024-07-30Asako MCCLOSKEY | pending |
| CRYSTALLINE FORMS OF A MENIN INHIBITORFiled as KURA ONCOLOGY, INC.2024-07-16ROGER PAUL BAKALE | pending |
| TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENINFiled as Kura Oncology, Inc.2024-06-18Francis BURROWS | pending |
| CRYSTALLINE FORMS OF A MENIN INHIBITORFiled as Kura Oncology, Inc.2024-06-03Roger Paul BAKALE | pending |
| FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERSFiled as KURA ONCOLOGY, INC.2024-05-30FRANCIS BURROWS | pending |
| METHODS OF TREATING SQUAMOUS CELL CARCINOMA WITH A FARNESYLTRANSFERASE INHIBITOR AND A PI3K INHIBITORFiled as KURA ONCOLOGY, INC.2024-05-07FRANCIS BURROWS | pending |
| METHODS OF TREATING ACUTE LEUKEMIAS WITH A MENIN INHIBITOR IN A COMBINATION THERAPYFiled as Kura Oncology, Inc.2024-05-02Daniel G. CORUM | pending |
| FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERSFiled as Kura Oncology, Inc.2024-04-26Francis Burrows | pending |
| METHODS OF TREATING NON-SMALL CELL LUNG CANCERFiled as KURA ONCOLOGY, INC.2024-04-18FRANCIS BURROWS | pending |
| MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAMEA61P 35/00, C07D 401/04, C07D 401/10, A61K 31/439, A61K 31/4704, A61K 31/4748, C07D 491/044, C07D 491/08, C07D 491/18Filed as Kura Oncology, Inc.2024-04-12Xuefeng Zhu | pending |
| FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERSFiled as Kura Oncology, Inc.2024-02-21Francis Burrows | pending |
| METHODS OF TREATING ACUTE LEUKEMIAS WITH A MENIN INHIBITOR IN A COMBINATION THERAPYFiled as Kura Oncology, Inc.2024-01-29Daniel G. Corum | pending |
| METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMAA61K 31/519, A61P 35/02, A61K 31/44, A61K 31/445, A61K 31/4523, A61K 31/453, A61K 31/454, A61K 31/4545, A61K 31/4725, A61K 31/505, A61K 31/5377Filed as KURA ONCOLOGY, INC.2024-01-19Francis BURROWS | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on KURA
Company overviewEverything on KURA in one place, with the price.SEC filingsWhat KURA's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat KURA's own officers and directors buy and sell.Planned salesSales KURA insiders have filed notice of.Executive payWhat KURA awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in KURA.Funds holding itWhich funds and ETFs hold KURA, and how big a bet.